Stock Ratings / Health Care / ALLO / earnings

AUTL (25) PROK (44) EDIT (37) CCCC (27) ⌘ Pro Terminal →

Allogene Therapeutics Inc. (ALLO) Next Earnings Date & Expected ±12.5% Move

Q: Is ALLO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Allogene Therapeutics Inc. (NASDAQ: ALLO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.25 (-3.85% 1D, market cap $431.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ALLO ranks #708 in composite RQD confidence.

Q: How does ALLO compare to AUTL and PROK in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ALLO carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AUTL (Autolus Therapeutics plc) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $420.5M) and PROK (ProKidney Corp. (Class A)) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $444.4M). Among the 5-stock peer group, ALLO leads on earnings multiple (N/A) while ALLO leads on capital efficiency (-35.0% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for ALLO?

Per ALLO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737287), Allogene Therapeutics Inc. generated $0 in revenue (-100.0% YoY), -$190.9M in net income, and -$149.6M in free cash flow against $415.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is ALLO trading relative to its 50-day, 200-day, and 52-week technical levels?

ALLO last traded at $1.25 (-3.85% on volume of 7,714,612 shares), positioning the stock -22.84% below its 50-day simple moving average ($1.62) and -36.87% below its 200-day simple moving average ($1.98). Across its 52-week range of $1.04 to $4.46, ALLO sits at the 6.1% percentile with a 14-day RSI of 29.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.09 to $1.41).

Q: When is ALLO's next earnings date?

Based on SEC filing cadence, Allogene Therapeutics Inc. (ALLO)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is ALLO stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ALLO, spanning a range between $1.09 and $1.41.

$1.25 -3.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.24

Allogene Therapeutics Inc. (ALLO) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $431.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.24 (-0.88%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALLO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY ALLO SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 29.3 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.46-10.3% Next Q

Q2 (-2Q)

Grade D$1.31-4.6% Next Q

Q3 (-1Q)

Grade D$1.25+0% Next Q

Current

Grade D-$1.25-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALLO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALLO currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.62) and Max Pain ($1.31) forces dealer call-delta covering toward $4.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALLO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALLO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.16 Expected Swing

MODEL EARNINGS SETUP GAUGE

ALLO Quantitative Pre-Earnings Setup: 38/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (38/100)Model Risk Weight (62/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$190.9M	-$149.6M	52%
FY 2024	2024-12-31	$22.0K	-$257.6M	-$201.0M	52%
FY 2023	2023-12-31	$95.0K	-$327.3M	-$237.7M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALLO)

✓Walkthrough of ALLO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALLO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.31%▼ DESCENDING CHANNEL

2026-10-30O $1.24H $1.26L $1.16C $1.25VOL 9.76M

RES: $2.11SUP: $1.12SMA50: $1.62SMA200: $1.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALLO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALLO Butterfly Map → + Track ALLO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALLO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALLO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALLO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALLO)

Health Care Rank #708 of 1016 ⚔️ AUTL vs ALLO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALLO vs. AUTL, PROK, EDIT, CCCC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Allogene Therapeutics Inc. (ALLO) ranks #708 by composite RQD confidence (38/100, grade D-) and #469 by equity capitalization ($431.9M). Within this direct 5-issuer industry benchmark cohort, ALLO leads on earnings valuation at N/A trailing P/E, while ALLO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PROK currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with ALLO at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALLO ACTIVE Allogene Therapeutics Inc.	D-	38/100	—	—	-35.0%	-3.85%	$431.9M	Benchmark Subject
AUTL Autolus Therapeutics plc	E	25/100	—	-27.8%	-35.0%	-3.07%	$420.5M	/autl-vs-allo →
PROK ProKidney Corp. (Class A)	D	44/100	—	—	-35.0%	-3.29%	$444.4M	/prok-vs-allo →
EDIT Editas Medicine Inc.	D-	37/100	—	—	-35.0%	-0.68%	$450.0M	/edit-vs-allo →
CCCC C4 Therapeutics Inc.	E	27/100	—	—	-35.0%	-2.80%	$406.0M	/cccc-vs-allo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001737287

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Allogene Therapeutics Inc. (ALLO) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $22.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$190.9M, operating cash flow of -$149.2M, and free cash flow of -$149.6M (+25.6% YoY). On the balance sheet, ALLO closed FY2025 with $415.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$190.9M	-$149.2M	-$149.6M	$415.9M	—
FY2024 (FY)	2024-12-31	$22.0K	-$257.6M	-$200.3M	-$201.0M	$548.7M	—
FY2023 (FY)	2023-12-31	$95.0K	-$327.3M	-$237.7M	-$237.7M	—	—

3. ALLO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALLO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Allogene Therapeutics Inc. (NASDAQ: ALLO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.25 (-3.85% 1D, market cap $431.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ALLO ranks #708 in composite RQD confidence.

How does ALLO compare to AUTL and PROK in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ALLO carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AUTL (Autolus Therapeutics plc) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $420.5M) and PROK (ProKidney Corp. (Class A)) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $444.4M). Among the 5-stock peer group, ALLO leads on earnings multiple (N/A) while ALLO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALLO?

Per ALLO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737287), Allogene Therapeutics Inc. generated $0 in revenue (-100.0% YoY), -$190.9M in net income, and -$149.6M in free cash flow against $415.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALLO trading relative to its 50-day, 200-day, and 52-week technical levels?

ALLO last traded at $1.25 (-3.85% on volume of 7,714,612 shares), positioning the stock -22.84% below its 50-day simple moving average ($1.62) and -36.87% below its 200-day simple moving average ($1.98). Across its 52-week range of $1.04 to $4.46, ALLO sits at the 6.1% percentile with a 14-day RSI of 29.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.09 to $1.41).

ALLO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ALLO's next earnings date?

Based on SEC filing cadence, Allogene Therapeutics Inc. (ALLO)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ALLO stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ALLO, spanning a range between $1.09 and $1.41.

Direct Sub-Reports: ALLO RQD Cockpit ALLO 12M Forecast ALLO Earnings & Move ALLO Dividends & DRIP ALLO Insiders & 13F ALLO Whale Options ALLO Profit Sankey ALLO News & Why